Technology Appraisal Reviews (TARs) conducted by Warwick Evidence

Connock M, Cummins E, Sutcliffe P, Court R, Johnson R, Grove A, Ngianga-Bakwin K, Mohiuddin S, and Clarke A. Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus: A Single Technology Appraisal. Warwick Evidence, 2011.

Connock M, Cummins E, Shyangdan D, Hall B, Grove A, Clarke A. Abiraterone acetate for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy: A Single Technology Appraisal. Warwick Evidence, 2012. reportLink opens in a new window

Cummins E, Shyangdan D, Royle P, Johnston R, Ho V, Briscoe S, Lois N, Waugh N. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema: A Single Technology Appraisal. Warwick Evidence, 2012. report

Royle P, Cummins E, Walker C, Chong S, Kandala,N, Waugh N. Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine: a single technology assessment. Warwick Evidence, 2012. reportLink opens in a new window

Sutcliffe, P., Connock, M., Shyangdan, D., Court, R., Ngianga-Bakwin, K., Clarke, A. (under review). A systematic review of evidence on malignant spinal metastates: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression. HTA monograph.

Gurung, T., Sutcliffe,P., Hall, B., Grove,A., (under review). Scoping review on the potential harms from aspirin given in low dose (<300mgs) for any indication). Warwick Evidence, 2011.

Waugh N, Cummins E, Shyangdan D, Court RA, Mohiuddin S. Long-acting exenatide in the treatment of type 2 diabetes: a single technology appraisal. Warwick Evidence, 2011. guidanceLink opens in a new window 

Shyangdan D, Clar, C, Ghouri, N, Henderson, R, Gurung, T, Preiss, D, Sattar, N, Fraser, A and Waugh, N. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Warwick Evidence, 2011.